Figure 3: ERK1/2 inhibitor suppresses LPS-induced NFκB activation in HMVEC.
HMVEC were pre-treated for 1 hour with ERK1/2 inhibitor (1μM) or vehicle, and then with LPS (10 ng/ml) in the continued presence of ERK1/2 inhibitor for 30 minutes. (A) Representative images of phospho-NF-κB and actin were detected by immunoblots (δ: normalized density of phospho-NF-κBtreatment/normalized density of phospho-NF-κBmedia). (B) Bar graphs showing the relative abundance of phospho-NF-κB after normalization to actin. n=4; *p ≤ 0.05; NS, not significant.